Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )
"We are thrilled to have someone with Satish's background and experienceas part of our regulatory leadership team," said Melanie Bruno, PhD, VicePresident, Global Regulatory Affairs, Quality and Safety. "His ability toanalyze the regulatory complexities of drug development and fashion a marketpositioning strategy to help ensure commercial success will provide awonderful resource to Kendle's customers."
Advertisement
Dr. Tripathi served most recently as the Director of Worldwide RegulatoryStrategy at Pfizer (formerly Pharmacia). Prior to that, he was a Director ofGlobal Regulatory Affairs at the Biosciences Division of Baxter HealthcareCorporation in charge of all global regulatory submissions within theRecombinant Strategic Business Unit. While at the U.S. Food and DrugAdministration, Dr. Tripathi served as a Pharmacology and Toxicology Reviewerwith an emphasis on oncology and pulmonary products.
Dr. Tripathi earned his doctorate from the University of Glasgow inScotland, his Master of Philosophy from Bhopal University in India andbachelor's and master's degrees from Jiwaji University at Gwalior, India. Hispost-doctoral fellowships include the Massachusetts Institute of Technology,Emory University Medical School and the Medical College of Wisconsin.
Dr. Tripathi will be based in Kendle's Chicago office.
About Kendle
Kendle International Inc. (Nasdaq: KNDL) is among the world's leadingglobal clinical research organizations. We deliver innovative and robustclinical development solutions -- from first-in-human studies through marketlaunch and surveillance -- to help the world's biopharmaceutical companiesmaximize product life cycles and grow market share.
Our global clinical development business is focused on five regions --North America, Europe, Asia/Pacific, Latin America and Africa -- to meetcustomer needs. We have conducted clinical trials and provided regulatory andpharmacovigilance services in more than 80 countries. The company was namedthe "Top CRO to Work With" in the Thomson CenterWatch 2007 Survey of U.S.Investigative Sites and named "Best CRO" for the second consecutive year byleading global pharmaceutical publication Scrip.
Additional information and investor kits are available upon request fromKendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from theCompany's Web site at http://www.kendle.com.
SOURCE Kendle International Inc.
